Advanced Clinical Experience. Personalized Care.
Independent clinical leadership backed by a PhD in Biochemistry & Pharmacokinetics, 25 years of clinical experience, and hospital and intensive care attending responsibilities.

Meet Your Provider
Adam T. Aroyo, PhD, AAPRN, FNP-BC, NP
Adam T. Aroyo is a board-certified Family Nurse Practitioner with autonomous practice authority in Florida and a PhD in Biochemistry & Pharmacokinetics. His 25 years of clinical experience span primary care, hospital medicine, intensive care, interventional cardiology, hormone optimization, and trauma flight medicine.
He also serves in hospital and ICU attending roles within his clinical privileges, bringing extensive experience in managing complex and critically ill patients to the personalized care offered at CHAI Health.
A 20-year U.S. Air Force combat veteran, he served his first 10 years as an enlisted Tactical Air Control Party (TACP) member and Joint Terminal Attack Controller (JTAC), including service in the Gulf War. He subsequently served 10 years as a commissioned Air Force Medical Officer during Operation Iraqi Freedom.
His combination of combat service, advanced military medical training, and extensive civilian clinical experience reflects a career dedicated to service, clinical excellence, and patient-centered care.
The CHAI Health Difference
Advanced Clinical Expertise. Comprehensive Patient Care. Transparent Pricing.
Advanced Clinical Experience
25 years of clinical experience spanning primary care, hospital medicine, intensive care, interventional cardiology, and trauma flight medicine—bringing advanced clinical insight to personalized outpatient care.
Hormone & Peptide Expertise
Individualized hormone and peptide-related care informed by advanced clinical experience and scientific training.
Comprehensive Medical Oversight
Cardiovascular health, metabolic function, medication safety, and whole-body considerations.
Transparent Medication Pricing
When clinically appropriate, compounded medications are sourced through licensed 503A pharmacies and offered with modest markups over pharmacy acquisition costs—helping make personalized treatment more accessible.

